Glycemic control aiming at normoglycemia, frequently referred to as 'strict glycemic control' (SGC), decreased mortality and morbidity of adult critically ill patients in two randomized controlled trials (RCTs). Five successive RCTs, however, failed to show benefit of SGC with one trial even reporting an unexpected higher mortality. Consequently, enthusiasm for the implementation of SGC has declined, hampering translation of SGC into daily ICU practice. In this manuscript we attempt to explain the variances in outcomes of the RCTs of SGC, and point out other limitations of the current literature on glycemic control in ICU patients. There are several alternative explanations for why the five negative RCTs showed no beneficial effects of SGC, apart from the possibility that SGC may indeed not benefit ICU patients. These include, but are not restricted to, variability in the performance of SGC, differences among trial designs, changes in standard of care, differences in timing (that is, initiation) of SGC, and the convergence between the intervention groups and control groups with respect to achieved blood glucose levels in the successive RCTs. Additional factors that may hamper translation of SGC into daily ICU practice include the feared risk of severe hypoglycemia, additional labor associated with SGC, and uncertainties about who the primarily responsible caregiver should be for the implementation of SGC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911685 | PMC |
http://dx.doi.org/10.1186/cc8966 | DOI Listing |
Acta Diabetol
January 2025
Endocrinology Department, University Hospital La Paz, Madrid, Spain.
Res Nurs Health
January 2025
Department of Internal Medicine and Center for Tissue Engineering, Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Taoyuan, Taiwan ROC.
Mobile health (mHealth) enables health-care professionals to assist patients with type 2 diabetes (T2D) in effective self-management of the disease. Using a quasi-experimental design, we evaluated the effectiveness of a nurse-led mHealth problem-solving program (mHealth-PSP) in enhancing problem-solving skills, improving emotional adaptation, and reducing glycated hemoglobin (HbA1c) levels in patients with T2D. The present study included 83 patients with T2D from two hospitals in northern Taiwan.
View Article and Find Full Text PDFJ Appl Physiol (1985)
January 2025
School of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong NSW 2522, Australia.
Objective: This study aimed to determine whether interrupting prolonged sitting with brief bouts of light-intensity activity (ISIT), undertaking structured high-intensity interval training (HIIT), or the combination of both interventions would elicit greater cardiometabolic benefits.
Methods: Seventeen healthy adults (22-50 years) were recruited to undertake three 2-week interventions in a random order: i) HIIT (6 HIIT sessions + <5000 steps following the session and on the next day), ii) ISIT (2.5 min light-intensity walking every hour for 12 h/day on weekdays), and iii) HIIT+ISIT.
Future Sci OA
December 2025
Faculty of Medicine, Thamar University, Dhamar, Yemen.
Aim: This study aims to assess the prevalence of depression among patients with diabetic neuropathy and identify contributing factors.
Methods: A cross-sectional descriptive design was used, recruiting 153 patients from outpatient clinics. Participants completed the Beck Depression Inventory II, Michigan Neuropathy Screening Instrument, and Douleur Neuropathique 4 questionnaires, with recent A1C results obtained from medical records.
J Diabetes Res
January 2025
Department of Nutrition and Food Technology, Jashore University of Science and Technology, Jashore, Bangladesh.
Mushrooms and fenugreek are widely used to reduce hyperglycemia, and fenugreek is also used as a culinary ingredient to enhance flavor and aroma. This study is aimed at investigating the underlying mechanisms of the hypoglycemic effects of mushrooms and fenugreek in a Type 2 diabetic rat model. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) functions to reduce hyperglycemia through insulin-independent pathways and protects beta-cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!